Industry Growth Insights published a new data on “PD-1 Inhibitor Market”. The research report is titled “PD-1 Inhibitor Market research by Types (Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab, Other), By Applications (Melanoma, Non-small Cell Lung Cancer (NSCLC), Urothelial Carcinoma, Classical Hodgkin Lymphoma, Renal Cell Carcinoma, Other), By Players/Companies Merck, Novartis, Onxeo, Sumitomo Dainippon Pharma, Taiwan Liposome Company, Tiziana Life Sciences, Genentech (Roche), AstraZeneca, Pfizer”.
Scope Of The Report
Report Attributes
Report Details
Report Title
PD-1 Inhibitor Market Research Report
By Type
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab, Other
By Application
Melanoma, Non-small Cell Lung Cancer (NSCLC), Urothelial Carcinoma, Classical Hodgkin Lymphoma, Renal Cell Carcinoma, Other
By Companies
Merck, Novartis, Onxeo, Sumitomo Dainippon Pharma, Taiwan Liposome Company, Tiziana Life Sciences, Genentech (Roche), AstraZeneca, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
196
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global PD-1 Inhibitor Market Report Segments:
The global PD-1 Inhibitor market is segmented on the basis of:
Types
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Melanoma, Non-small Cell Lung Cancer (NSCLC), Urothelial Carcinoma, Classical Hodgkin Lymphoma, Renal Cell Carcinoma, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Novartis
- Onxeo
- Sumitomo Dainippon Pharma
- Taiwan Liposome Company
- Tiziana Life Sciences
- Genentech (Roche)
- AstraZeneca
- Pfizer
Highlights of The PD-1 Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pembrolizumab
- Nivolumab
- Atezolizumab
- Durvalumab
- Avelumab
- Other
- By Application:
- Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Urothelial Carcinoma
- Classical Hodgkin Lymphoma
- Renal Cell Carcinoma
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the PD-1 Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PD-1 inhibitors are a type of cancer treatment that work by blocking the PD-1 receptor, which helps tumors to grow and spread.
Some of the key players operating in the pd-1 inhibitor market are Merck, Novartis, Onxeo, Sumitomo Dainippon Pharma, Taiwan Liposome Company, Tiziana Life Sciences, Genentech (Roche), AstraZeneca, Pfizer.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 PD-1 Inhibitor Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 PD-1 Inhibitor Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 PD-1 Inhibitor Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the PD-1 Inhibitor Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global PD-1 Inhibitor Market Size & Forecast, 2018-2028 4.5.1 PD-1 Inhibitor Market Size and Y-o-Y Growth 4.5.2 PD-1 Inhibitor Market Absolute $ Opportunity
Chapter 5 Global PD-1 Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 PD-1 Inhibitor Market Size Forecast by Type
5.2.1 Pembrolizumab
5.2.2 Nivolumab
5.2.3 Atezolizumab
5.2.4 Durvalumab
5.2.5 Avelumab
5.2.6 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global PD-1 Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 PD-1 Inhibitor Market Size Forecast by Applications
6.2.1 Melanoma
6.2.2 Non-small Cell Lung Cancer (NSCLC)
6.2.3 Urothelial Carcinoma
6.2.4 Classical Hodgkin Lymphoma
6.2.5 Renal Cell Carcinoma
6.2.6 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global PD-1 Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 PD-1 Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America PD-1 Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America PD-1 Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America PD-1 Inhibitor Market Size Forecast by Type
9.6.1 Pembrolizumab
9.6.2 Nivolumab
9.6.3 Atezolizumab
9.6.4 Durvalumab
9.6.5 Avelumab
9.6.6 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America PD-1 Inhibitor Market Size Forecast by Applications
9.10.1 Melanoma
9.10.2 Non-small Cell Lung Cancer (NSCLC)
9.10.3 Urothelial Carcinoma
9.10.4 Classical Hodgkin Lymphoma
9.10.5 Renal Cell Carcinoma
9.10.6 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe PD-1 Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe PD-1 Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe PD-1 Inhibitor Market Size Forecast by Type
10.6.1 Pembrolizumab
10.6.2 Nivolumab
10.6.3 Atezolizumab
10.6.4 Durvalumab
10.6.5 Avelumab
10.6.6 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe PD-1 Inhibitor Market Size Forecast by Applications
10.10.1 Melanoma
10.10.2 Non-small Cell Lung Cancer (NSCLC)
10.10.3 Urothelial Carcinoma
10.10.4 Classical Hodgkin Lymphoma
10.10.5 Renal Cell Carcinoma
10.10.6 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific PD-1 Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific PD-1 Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific PD-1 Inhibitor Market Size Forecast by Type
11.6.1 Pembrolizumab
11.6.2 Nivolumab
11.6.3 Atezolizumab
11.6.4 Durvalumab
11.6.5 Avelumab
11.6.6 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific PD-1 Inhibitor Market Size Forecast by Applications
11.10.1 Melanoma
11.10.2 Non-small Cell Lung Cancer (NSCLC)
11.10.3 Urothelial Carcinoma
11.10.4 Classical Hodgkin Lymphoma
11.10.5 Renal Cell Carcinoma
11.10.6 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America PD-1 Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America PD-1 Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America PD-1 Inhibitor Market Size Forecast by Type
12.6.1 Pembrolizumab
12.6.2 Nivolumab
12.6.3 Atezolizumab
12.6.4 Durvalumab
12.6.5 Avelumab
12.6.6 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America PD-1 Inhibitor Market Size Forecast by Applications
12.10.1 Melanoma
12.10.2 Non-small Cell Lung Cancer (NSCLC)
12.10.3 Urothelial Carcinoma
12.10.4 Classical Hodgkin Lymphoma
12.10.5 Renal Cell Carcinoma
12.10.6 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) PD-1 Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) PD-1 Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) PD-1 Inhibitor Market Size Forecast by Type
13.6.1 Pembrolizumab
13.6.2 Nivolumab
13.6.3 Atezolizumab
13.6.4 Durvalumab
13.6.5 Avelumab
13.6.6 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) PD-1 Inhibitor Market Size Forecast by Applications
13.10.1 Melanoma
13.10.2 Non-small Cell Lung Cancer (NSCLC)
13.10.3 Urothelial Carcinoma
13.10.4 Classical Hodgkin Lymphoma
13.10.5 Renal Cell Carcinoma
13.10.6 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 PD-1 Inhibitor Market: Competitive Dashboard
14.2 Global PD-1 Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Novartis
14.3.3 Onxeo
14.3.4 Sumitomo Dainippon Pharma
14.3.5 Taiwan Liposome Company
14.3.6 Tiziana Life Sciences
14.3.7 Genentech (Roche)
14.3.8 AstraZeneca
14.3.9 Pfizer